Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325854 | 1.00 | CTSL (0.46) | CTSLELANEACESYKPREP | |
| SCHEMBL13338627 | 1.00 | CTSL (0.46) | CTSLELANEACESYKPREP | |
| SCHEMBL2325851 | 1.00 | CTSL (0.46) | CTSLELANEACESYKPREP | |
| SCHEMBL8281458 | 0.93 | CTSL (0.54) | CTSLELANEACE | |
| SCHEMBL30457353 | 0.93 | ACE (0.44) | ACEPREPCASP1CASP3CASP2 | |
| SCHEMBL31366192 | 0.91 | ACE (0.45) | CTSLACEPREPCASP1CASP3 | |
| SCHEMBL25272563 | 0.91 | ACE (0.52) | ACEPREPCASP1CASP3CASP2 | |
| SCHEMBL3795335 | 0.91 | ACE (0.52) | ACEPREPCASP1CASP3CASP2 | |
| SCHEMBL25225361 | 0.91 | ACE (0.52) | ACEPREPCASP1CASP3CASP2 | |
| SCHEMBL3795326 | 0.91 | ACE (0.52) | ACEPREPCASP1CASP3CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871904-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140107318-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637457-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2194043-B1 | Processes | VERTEX PHARMA (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130172276-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130096277-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
| US-8399615-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2364970-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2357170-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7776887-B2 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100174077-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2194043-A2 | Processes and intermediates | Vertex Pharmceuticals Incorporated (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1934179-B1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMA (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-11 | — | — | US | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096277-A1 | PROCESSES AND INTERMEDIATES | CYP1B1, CYP3A7, CYP7A1 | CTSL 4050/4885ELANE 3613/4885ACE 1540/4885 |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | CTSL 17/4885ELANE 123/4885ACE 67/4885 |
| US-20130172276-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | CTSL 17/4885ELANE 123/4885ACE 67/4885 |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | PRSS1, CTRL, TMPRSS2 | CTSL 19/4885ELANE 503/4885ACE 89/4885 |
| US-20100174077-A1 | Processes and intermediates | TFPI, SPINT2, SERPINB1 | CTSL 17/4885ELANE 123/4885ACE 67/4885 |
| US-20140107318-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | CTSL 17/4885ELANE 123/4885ACE 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.